Media & Resources

News coverage on the results of a Phase I IAVI HIV vaccine clinical trial reflects public interest in vaccine development amid the ongoing COVID-19 pandemic.

IAVI recognizes the Government of India for their unwavering support of the development of safe, effective, accessible, preventive HIV vaccines and biomedical prevention products for use throughout the world.

Failure to meet commitments for TB research is not inevitable; the global COVID-19 response may show us the way.

IAVI CEO Mark Feinberg charts future HIV-1 vaccine development efforts in NEJM.

IAVI and partners recently held a webinar on challenges and opportunities for R&D of innovative biomedical treatments for COVID-19.

Spotlighting the work of IAVI’s female scientists and global advocates who work to ensure HIV prevention and care reaches adolescent girls and young women.

Watch our explainer videos describing why we need an HIV vaccine, the vaccine development process, and the concept of vaccine-induced seropositivity.

Focus on access, innovation, communities, and partnerships, say leading voices.